ClinicalTrials.gov
ClinicalTrials.gov Menu

Allo BMT in Advanced Leukemia or High Grade Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00186290
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : October 11, 2010
Sponsor:
Information provided by:
Stanford University

Brief Summary:
To evaluate the role of ablative allogeneic hematopoietic cell transplantation in the treatment of advanced leukemia or lymphoma.

Condition or disease Intervention/treatment Phase
Lymphoma, Non-Hodgkin Leukemia Blood and Marrow Transplant (BMT) Lymphomas: Non-Hodgkin Procedure: ablative allogeneic hematopoietic cell transplantation Not Applicable

Detailed Description:
To determine the disease free survival and overall survival of patients with ALL and ANLL after induction failure, in relapse, or subsequent remission from CML in several phases or recurrent lymphoblastic lymphoma who receive fractionated TBI, etoposide and cyclophosphamide followed by allogenic bone marrow grafting from histocompatible sibling donors. Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients with Advanced Leukemia or High Grade Lymphoma

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 145 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients With Advanced Leukemia or High Grade Lymphoma
Study Start Date : December 1989
Actual Primary Completion Date : October 2009
Actual Study Completion Date : October 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Leukemia Lymphoma
U.S. FDA Resources




Primary Outcome Measures :
  1. overall survival [ Time Frame: october 2009 ]
  2. disease free survival [ Time Frame: October 2009 ]

Secondary Outcome Measures :
  1. early and late toxicities of the treatment regimen [ Time Frame: October 2009 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 50 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:HLA identical donor

  • adequate organ function
  • other life threatening disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00186290


Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Robert Lowsky Stanford University

Responsible Party: Robert Lowsky, Stanford University School of Medicine
ClinicalTrials.gov Identifier: NCT00186290     History of Changes
Other Study ID Numbers: BMT34
74165
First Posted: September 16, 2005    Key Record Dates
Last Update Posted: October 11, 2010
Last Verified: October 2010

Additional relevant MeSH terms:
Lymphoma
Leukemia
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases